Focus on Mid-size European/Biotech Deals
Executive Summary
Mid-sized European pharmaceutical dealmakers tend to be more conservative than the rest of the industry, particularly when it comes to upfront payments in alliances. But an analysis of upfront payments we've done seems to reveal that these mid-sized players may be warming up to the concept.